$0.92+0.01 (+1.1%)
Updated May 5, 2025 10:38AM EDT
HOWL Price
$0.91
Fair Value Price
$1.61
Market Cap
$40.57M
52 Week Low
$0.60
52 Week High
$6.24
P/E
-0.56x
P/B
0.55x
P/S
34.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.89M
Earnings
-$70.52M
Gross Margin
100%
Operating Margin
-3,493.85%
Profit Margin
-3,740.8%
Debt to Equity
0.73
Operating Cash Flow
-$56M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HOWL Overview
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics that stimulate the body's immune system for the treatment of cancer. The company, through its... read more
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HOWL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HOWL
Ranked#377 of 467
Ranked#377 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.00 | A | |
| $8.21 | A | |
| $24.84 | A |
Be the first to know about important HOWL news, forecast changes, insider trades & much more!
HOWL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HOWL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HOWL ($0.91) is undervalued by 43.93% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HOWL ($0.91) is significantly undervalued by 43.93% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HOWL due diligence checks available for Premium users.
Valuation
HOWL fair value
Fair Value of HOWL stock based on Discounted Cash Flow (DCF)
Price
$0.91
Fair Value
$1.61
Undervalued by
43.62%
HOWL ($0.91) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HOWL ($0.91) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HOWL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.56x
Industry
-201.8x
Market
29.31x
HOWL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
4.53x
HOWL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HOWL's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.4M
Profit Margin
0%
HOWL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HOWL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$126.9M
Liabilities
$53.5M
Debt to equity
0.73
HOWL's short-term assets ($113.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOWL's short-term assets ($113.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOWL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HOWL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.3M
Investing
-$123.0k
Financing
$2.5M
HOWL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HOWL vs Biotech Stocks
Werewolf Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.